NasdaqCM:NEOHealthcare
Assessing NeoGenomics (NEO) Valuation After Board Change Bringing In Diagnostics Veteran Jack Kenny
NeoGenomics (NEO) shares are back in focus after the company announced Board changes, with long serving director Dr. Alison L. Hannah resigning and diagnostics veteran John P. “Jack” Kenny taking her seat.
See our latest analysis for NeoGenomics.
The Board reshuffle follows a period of firm share price momentum, with NeoGenomics posting a 40.30% 3 month share price return and a 4.20% 1 year total shareholder return from a current share price of $13.16.
If this kind of leadership change has...